Unity Health Toronto

Arch Biopartners Inc. announces the start of patient recruitment and dosing in Canada for the Phase II trial of LSALT peptide, targeting cardiac surgery-associated acute kidney injury (CS-AKI). The University of Calgary has already dosed the first patient, and Toronto hospitals are finalizing approvals. The trial aims to evaluate the percentage of subjects with AKI within seven days post-surgery, using KDIGO criteria.

Arch Biopartners announces Alberta Health Services approval for Phase II trial of LSALT peptide to prevent and treat cardiac surgery-associated acute kidney injury (CS-AKI). The trial, targeting 240 patients, is set to begin recruitment in September at multiple international sites.

The Royal Society of Canada Working Group, in partnership with CIHR, is conducting an international knowledge exchange initiative to develop actionable recommendations for strengthening Canada's health research system post-pandemic. The initiative involves sessions with various stakeholders to gather input on strategies addressing four themes from the WHO research system framework: governance/stewardship, capacity building, financing, and producing/using research. Surveys are used to collect data on organizational strategies, modifications for pandemic recovery, and competing interests, with results informing the development of recommendations.